Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com > EOD
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by KeepGoingon Jul 18, 2018 3:34pm
114 Views
Post# 28334709

RE:RE:EOD

RE:RE:EODMy reading is that the trial is positive, conclusively. All we are waiting for is the announcement of detail, following patent rights, after which peers will be able to review and comment. I doubt peers will shoot down the analysis. The share price does not reflect fundamentals because of the recent shorting. Perversely the price will rise on the announcement of the details because of the hype and herd mentality of trading penny stocks. It shouldn't in theory but it will. Phase 1 has beeen announced as a success. No more to it. GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities